AGORACOM News Flash

AGORACOM WIRE - WEDNESDAY MAY 30TH, 2012

GOLDEN HOPE MINES (TSXV:GNH) Confirms High Grade Intersection of 64.1 g/t Au (Gold) over 1m Read More

The screen metallic analysis returned 82 g/t Au for an average grade of 93.5 g/t Au.
Two additional fire assays on the original pulp done prior to the screen metallic analyses returned 0.22 g/t Au and 0.12 g/t Au for an average fire assay grade of 0.41 g/t Au. The weighted average of all the fire assays and screen metallic assays from this 1-metre section in hole BD2011-184 is 64.1 g/t Au.

Sonomax® eers™ Custom Earbuds Announces Sponsorship of MUTEK 2012

Mutek provides an essential platform for 150 performers to showcase forward-thinking electronic music programming and new media to more than 25,000 attendees
Read Full Press Release; Read Why Sonomax?
Jump Into Active Discussion Forum
*Sponsor*

CONTINENTAL ENERGY Geothermal Energy Project Receives US$ 11.5 Million Grant Read More * Client

AGORACOM Launches Graphite Stocks Blog

NEWS - Haemacure Announces Details of its Annual General and Special Meeting of Shareholders

posted on Apr 07, 08 04:18AM

Haemacure Announces Details of its Annual General and Special Meeting of Shareholders

HAE:TSX

MONTREAL, April 7, 2008 -- Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company, will hold its Annual General and Special Meeting of Shareholders on Wednesday, April 9, 2008 at 4 p.m. at The National Club, 303 Bay Street, Toronto, Ontario.

Presentation

Mr. Joseph Galli, Chairman and Chief Executive Officer of Haemacure, will report on accomplishments of 2007 and provide an outlook for 2008 and beyond, including a report on Haemacure's clinical programs for its two proprietary, human product candidates, a fibrin sealant and an active, topical hemostatic agent (thrombin).

Live Webcast

For those who are unable to attend in person, Haemacure will simultaneously host a live webcast of the presentation with slides, at http://events.snwebcastcenter.com/haemacure/20080409/.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant. Follow-on development will focus on surgical hemostats, adhesion prevention, regenerative medecine, drug delivery and combinations with biomaterials. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.